Journal
HUMAN VACCINES
Volume 6, Issue 11, Pages 881-887Publisher
LANDES BIOSCIENCE
DOI: 10.4161/hv.6.11.12849
Keywords
meningococcal disease; CRM-197; Menveo; Menactra; conjugate vaccine; Neisseria meningitidis
Categories
Funding
- Novartis Vaccines
- Merck
- sanofi pasteur
- Protein Sciences
- GlaxoSmithKline
- Chiron Novartis
- MedImmune
- Diagnostics
Ask authors/readers for more resources
The persistence of human bactericidal activity (hSBA) responses in adolescents was assessed 22 months after vaccination with one dose of Menveo (R) (MenACWY-CRM; Novartis) or Menactra (R) (MCV4) (Sanofi Pasteur). The proportion of subjects with hSBA titers >= 8 was significantly higher among recipients of MenACWY-CRM than MCV4 for serogroups A, W-135 and Y.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
